Sort
48,018 grants matching “immunotherapy”
Intravital assessment of Borrelia burgdorferi immune clearance in skin
$389,683Ronald Mark Wooten · University Of Toledo Health Sci Campus · R01 · FY2016 · AI
Liquid biopsy of the lung to profile lung cancer
$389,670Viswam Siva Nair · Fred Hutchinson Cancer Center · U01 · FY2023 · CA
Liquid biopsy of the lung to profile lung cancer
$389,670Viswam Siva Nair · Fred Hutchinson Cancer Center · U01 · FY2022 · CA
Understanding regulatory defects T1D: natural history and impact of therapy
$389,663Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · RC4 · FY2010 · DK
Pro-tumor functions of neutrophils in squamous cell lung cancer
$389,613Trudy Gale Oliver · University Of Utah · R01 · FY2020 · CA
Pro-tumor functions of neutrophils in squamous cell lung cancer
$389,613Trudy Gale Oliver · University Of Utah · R01 · FY2021 · CA
Investigation of T cell responses to immunotherapy using class II tetramers
$389,602William W. Kwok · Benaroya Research Inst At Virginia Mason · R01 · FY2014 · AI
Birc5 as a regulator of NK cell development and immune function
$389,575Aimee Melissa Beaulieu · Rbhs-New Jersey Medical School · R01 · FY2021 · HL
Birc5 as a regulator of NK cell development and immune function
$389,575Aimee Melissa Beaulieu · Rbhs-New Jersey Medical School · R01 · FY2019 · HL
Birc5 as a regulator of NK cell development and immune function
$389,575Aimee Melissa Beaulieu · Rbhs-New Jersey Medical School · R01 · FY2022 · HL
Birc5 as a regulator of NK cell development and immune function
$389,575Aimee Melissa Beaulieu · Rbhs-New Jersey Medical School · R01 · FY2020 · HL
Birc5 as a regulator of NK cell development and immune function
$389,575Aimee Melissa Beaulieu · Rutgers Biomedical And Health Sciences · R01 · FY2023 · HL
Alpha-Particle Immunotherapy of Cancer
$389,561David A Scheinberg · Sloan-Kettering Inst Can Research · R01 · FY2007 · CA
Transport Oncophysics Core
$389,506Haifa Shen · Methodist Hospital Research Institute · U54 · FY2019 · CA
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC
$389,502Catherine Ju-Ying Wu · Beth Israel Deaconess Medical Center · P50 · FY2024 · CA
Immunomodulatory Effects of Heterochiral Biomaterials
$389,487Jai Rudra · University Of Texas Med Br Galveston · R01 · FY2018 · AI
Targeting the vasculature to enhance anti-tumor immunity
$389,460Andrew Carl Dudley · University Of Virginia · R01 · FY2023 · CA
Function of Aire-dependent regulatory T cells in immune tolerance
$389,432Peter Aidan Savage · University Of Chicago · R01 · FY2016 · AI
Function of Aire-dependent regulatory T cells in immune tolerance
$389,432Peter Aidan Savage · University Of Chicago · R01 · FY2019 · AI
Function of Aire-dependent regulatory T cells in immune tolerance
$389,432Peter Aidan Savage · University Of Chicago · R01 · FY2017 · AI
Regulation of Lymphocyte Development by HLH Proteins
$389,432Barbara Lynne Kee · University Of Chicago · R01 · FY2018 · AI
Regulation of Lymphocyte Development by HLH Proteins
$389,432Barbara Lynne Kee · University Of Chicago · R01 · FY2017 · AI
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
$389,423Cun-Yu Wang · University Of California Los Angeles · R01 · FY2024 · DE
Targeting PPT1 in the Tumor Microenvironment
$389,391Ravi K Amaravadi · Wistar Institute · P01 · FY2020 · CA
MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
$389,386Craig Lee Slingluff · University Of Virginia · U01 · FY2014 · CA